A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis

NCT03219437 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: risankizumab
DRUG: methotrexate

Sponsor

AbbVie